HEMLIBRA®▼(emicizumab) presentations on haemophilia patient care and management
Healthcare professionals are invited to watch the videos below to learn more about haemophilia patient care and management.
The European Congress on Thrombosis and Haemostasis (ECTH) 2019 videos are three case presentations that highlight the challenges faced by people with haemophilia A, and consider the potential benefits of HEMLIBRA in these patients.
In the Horizons virtual meeting series, expert speakers discuss their treatment experience with HEMLIBRA, share current data, and explore patient case studies.
The International Society on Thrombosis and Haemostasis (ISTH) 2019 congress highlights show expert healthcare professionals sharing their thoughts on the meeting.
Case presentations from ECTH 2019
Dr Michael Callaghan discusses the management of breakthrough bleeds in a patient receiving HEMLIBRA, and reviews HEMLIBRA annualised bleed rate data.
Dr Gerry Dolan presents the case of a patient who was limiting physical activity to minimise bleeding events, and discusses the potential benefits of HEMLIBRA in this patient.
Professor Guy Young shares the case of a paediatric patient with venous access problems leading to poor adherence, and discusses the route of administration and dosing options with HEMLIBRA.
Videos recorded 2–4 October 2019. Data correct at time of presentation.
Patient and caregiver management, 16 October 2019
Dr Jayanthi Alamelu and Cathy Harrison discuss how consultants and nurses can take into consideration the impact on caregivers and families, as well as the individual patient, when managing treatments.
Videos recorded on 16 October 2019. Data correct at time of presentation.
Latest data on HEMLIBRA, 16 July 2019
Immune tolerance induction (ITI), 26 June 2019
Dr Mary Mathias shares her perspective from Great Ormond Street by discussing a HEMLIBRA patient who is on low dose ITI. Dr Carmen Escuriola-Ettingshausen presents five patient cases from Frankfurt where HEMLIBRA has been added to a low dose ITI regimen.
Videos recorded on 26 June 2019. Data correct at time of presentation.
Implications on surgery, 16 May 2019
ISTH 2019 congress highlights
Videos recorded 6–10 July 2019. Data correct at time of presentation.
Dr Michael Callaghan, Associate Professor of Paediatrics, Wayne State University and the Children’s Hospital of Michigan, Detroit
Dr Callaghan received his medical degree from Wayne State University. He then completed his paediatric residency and paediatric haematology/oncology fellowship at the Children’s Hospital of Michigan, where he is currently an associate professor of paediatrics and director of the Pediatric Sickle Cell Center. Dr Callaghan is also a board-certified paediatric haematologist with a focus in benign haematology.
He cares for more than 100 children and adults with haemophilia and has served as medical director of the Camp Bold Eagle haemophilia camp.
Dr Callaghan participates in basic, translational and clinical research and has more than 50 publications in journals such as Haemophilia, Blood, Nature Genetics and The New England Journal of Medicine.
Dr Gerry Dolan, Centre Director, Guy’s and St Thomas’ NHS Foundation Trust
Dr Dolan qualified from Glasgow University Medical School and held training posts in internal medicine and haematology in Glasgow, Edinburgh and Sheffield before being appointed consultant haematologist at Nottingham University Hospital. He was head of the haemostasis and thrombosis service in Nottingham until 2015, before his current role as centre director at St Thomas’ Hospital, London.
He has been on the executive committee of the United Kingdom Haemophilia Centre Doctors Organisation since 1997 and was the chairman until October 2015. He was also previously president of the British Society of Haemostasis and Thrombosis (BSHT) and chair of the European Haemophilia Therapy Strategy Board (EHTSB). He is the co-chair of the ADVANCE group (a collaboration of European physicians, interested in the care of older adults with haemophilia).
His interests include clinical outcomes in haemophilia, management of older adults with haemophilia and molecular aspects of bleeding disorders.
Professor Guy Young, Director, Hemostasis and Thrombosis Center, Children’s Hospital Los Angeles
Dr Young received his medical degree from the State University of New York at Stony Brook School of Medicine. He undertook a residency in paediatrics at Schneider Children’s Hospital at Long Island Jewish Medical Center, Albert Einstein College of Medicine in New York, before completing his fellowship in paediatric haematology/oncology at Children’s National Medical Center, George Washington University School of Medicine.
He is currently director of the Hemostasis and Thrombosis Center at Children’s Hospital Los Angeles and professor of paediatrics at the University of Southern California’s Keck School of Medicine.
Dr Young’s research activities include clinical trials in haemophilia, the use of novel anticoagulants in children, and the development of global haemostasis assays to monitor the effects of medications used to treat bleeding in haemophilia. He has published many journal articles, abstracts, and textbook chapters and has delivered lectures, workshops, and presentations at national and international meetings.
He is a board member and past chair of the programme committee for the American Society of Pediatric Hematology/Oncology, and also a past chair of the programme committee for the Hemophilia and Thrombosis Research Society. He is chair of the Scientific and Standardization Committee on Factor VIII, Factor IX, and Rare Bleeding Disorders of the International Society on Thrombosis and Haemostasis and also serves on the scientific subcommittee on Hemostasis for the American Society of Hematology. He was awarded the National Hemophilia Foundation Physician of the Year Award in 2013.
Dr Jayanthi Alamelu, Consultant Paediatric Haematologist at Evelina London Children’s Hospital, Guy’s and St Thomas’ NHS Foundation Trust
Dr Alamelu completed her training in paediatric haematology at St Mary’s Hospital and Great Ormond Street Hospital, London, before starting at Evelina Children’s Hospital as a consultant in paediatric haematology in 2009. She is the lead for the South London Paediatric Haemophilia Network and is principal investigator for a number of paediatric haemophilia trials. Dr Alamelu also runs the Paediatric Thrombosis Registry.
With particular expertise in haemophilia and bleeding disorders in children, paediatric thrombosis and general paediatric haematology, Dr Alamelu’s research interests also cover thrombosis in neonates.
Dr Alamelu has authored and co-authored a number of publications covering a range of bleeding and platelet disorders, including articles in the British Journal of Haematology and Haemophilia. She also became a member of the United Kingdom Haemophilia Centre Doctors’ Organisation Paediatric Working Party when it was reformed in 2017.
Cathy Harrison, Advanced Nurse Practitioner, Sheffield Adult Haemophilia and Thrombosis Centre
Cathy Harrison has been a trustee of Haemnet since 2014, has served on the Haemophilia Nurses Association Committee since 2012, taking on the role of chair this year, and is currently undertaking her Master’s degree. She co-created and taught on the Contemporary Care Course for People with Bleeding Disorders and is on the United Kingdom Haemophilia Centre Doctors’ Organisation peer review and comorbidities working parties.
Debra Pollard, Lead Nurse Specialist, Royal Free London NHS Foundation Trust
Debra Pollard is Lead Nurse Specialist at the Katharine Dormandy Haemophilia and Thrombosis Centre, at the Royal Free. Since joining the Haemophilia Centre in 1991, Debra has been involved with the introduction of innovations in haemophilia treatment and care, from the introduction of prophylaxis and recombinant clotting factors, through to gene therapy and disruptive therapies. Debra led the Community Nursing Service and Home Treatment Training Programme for many years, before taking on her current Advanced Nursing Practice and leadership role.
Debra has a particular interest in the quality of life of those living with bleeding disorders. She believes there is a growing need for qualitative research, to ensure a better understanding of the real life issues for the bleeding disorders community.
Dr Jecko Thachil, Consultant Haematologist, Manchester Royal Infirmary
Dr Thachil is a consultant in haemostasis and thrombosis at the Manchester Royal Infirmary and honorary senior lecturer at Liverpool School of Tropical Medicine. His research is focused on the role of the interaction of platelets with white cells, in inflammation and sepsis. Also in new therapies in haemophilia, anticoagulation in kidney disease and expanding the speciality in low- and middle-income countries.
Internationally, he has served as the chairman of the disseminated intravascular coagulation subcommittee of the International Society of Thrombosis and Haemostasis and was recently identified to be among the top three healthcare professionals in the world, in this area.
He has published over 250 peer-reviewed papers, served as reviewer for 25 journals and edited the popular books Haematology in Critical Care and Handbook of Venous Thromboembolism. He has also written several book chapters.
Dr Mary Mathias, Consultant Paediatric Haematologist, Great Ormond Street Hospital, London
Dr Mathias has been a consultant in paediatric haematology, specialising in haemostasis and thrombosis, since 2006. She works at Great Ormond Street and the Royal Free Hospitals, as part of a team looking after children and young people with inherited bleeding disorders.
Particular interests include the management of children and adolescents with FVIII and FIX inhibitors and rare bleeding disorders. Her current research areas involve clinical trials of new clotting factor concentrates and collection of registry data, to demonstrate longer term outcomes of regular treatment for children with haemophilia.
Dr Mathias has also authored and co-authored a number of publications, including guidelines for the management of rare coagulation disorders. She is a member of the United Kingdom Haemophilia Centre Doctors’ Organisation Paediatric Working Party.
Dr Carmen Escuriola-Ettingshausen, Children’s Hospital of the Johann Wolfgang Goethe-University Hospital, Frankfurt, Germany
Dr Escuriola-Ettingshausen is the director of the HZRM Haemophilia Centre Rhein-Main, Frankfurt-Mörfelden, Germany. She graduated in medicine at the Johann Wolfgang Goethe-University in Frankfurt from 1985 to 1992. After that, she became resident at the Comprehensive Care Centre for thrombosis and haemostasis of the Children’s Hospital at University Hospital of Frankfurt in the department of paediatrics until 1996, and obtained the doctor title in 1995. There, she performed specialist’s training in paediatrics until 2000, becoming a staff member until 2012. She then founded the Haemophilia Centre Rhein-Main.
Dr Escuriola-Ettingshausen’s clinical interests include haemorrhagic disorders with a focus on haemophilias, thrombosis, congenital immunodeficiencies, and hereditary angioedema, in both paediatric and adult patients.
Her research interests are haemorrhagic disorders, particularly in the treatment of haemophilia, with and without inhibitors. She is a member of the German, Swiss and Austrian Society For Thrombosis and Haemostasis Research, International Society for Thrombosis and Haemostasis and the International Prophylaxis Study Group.
Julia Spires, Clinical Nurse Specialist, Great Ormond Street Hospital, London
Julia Spires has been part of the Great Ormond Street Haemophilia Nursing Team since 2012 and continues to work on her Master’s in Advanced Practice. Julia’s special interests include the teaching and training of parents and children using home treatments, to help them gain the maximum independence their treatment affords. Furthermore, Julia has extensive experience in the management of inhibitors.
▼This medicinal product is subject to additional monitoring. This will allow quick identification of new safety information. Healthcare professionals are asked to report any suspected adverse reactions. Adverse events should be reported. Reporting forms and information can be found at www.mhra.gov.uk/yellowcard or search for MHRA Yellow Card in the Google Play or Apple App Store. Adverse events should also be reported to Roche Products Ltd. Please contact Roche Drug Safety Centre by emailing email@example.com or calling +44 (0)1707 367554.
As Hemlibra is a biological medicine, healthcare professionals should report adverse reactions by brand name and batch number.
BSHT, British Society of Haemostasis and Thrombosis; ECTH, European Congress on Thrombosis and Haemostasis; EHTSB, European Haemophilia Therapy Strategy Board; FVIII, Factor VIII; FIX, Factor IX; ISTH, International Society on Thrombosis and Haemostasis.
Date of preparation: March 2020